Qube Research & Technologies LTD Zymeworks Inc. Transaction History

Qube Research & Technologies LTD

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$4.65 - $7.43 $437,034 - $698,315	-93,986 Reduced 66.81%	46,683 $287,000
Q2 2022 Aug 15, 2022	BUY	$4.82 - $7.7 $83,448 - $133,310	17,313 Added 14.03%	140,669 $746,000
Q1 2022 May 09, 2022	BUY	$6.0 - $16.98 $740,136 - $2.09 Million	123,356 New	123,356 $808,000
Q3 2021 Nov 12, 2021	SELL	$27.35 - $37.28 $303,038 - $413,062	-11,080 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$26.5 - $38.23 $227,343 - $327,975	-8,579 Reduced 43.64%	11,080 $384,000
Q1 2021 May 14, 2021	BUY	$29.83 - $56.81 $228,766 - $435,675	7,669 Added 63.96%	19,659 $621,000
Q4 2020 Feb 16, 2021	BUY	$39.12 - $54.99 $469,048 - $659,330	11,990 New	11,990 $567,000
Q3 2020 Nov 12, 2020	SELL	$29.21 - $46.58 $373,391 - $595,432	-12,783 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$33.67 - $40.0 $430,403 - $511,320	12,783 New	12,783 $461,000
Q1 2020 May 15, 2020	SELL	$24.28 - $49.8 $196,546 - $403,131	-8,095 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$24.84 - $45.46 $201,079 - $367,998	8,095 New	8,095 $368,000

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $903M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.